真实世界生脉注射液治疗9215例老年心血管疾病的临床特征及联合用药研究

doi:10.19803/j.1672-8629.2022.01.08

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (1): 36-40.
DOI: 10.19803/j.1672-8629.2022.01.08

• 真实世界老年/儿童患者应用中成药的现状研究专栏 • 上一篇下一篇

真实世界生脉注射液治疗9215例老年心血管疾病的临床特征及联合用药研究

孙春全¹, 谢雁鸣^1,*, 侯恒悦²

¹中国中医科学院,中医临床基础医学研究所,北京 100700;
²中国人民大学统计学院,北京 100872

收稿日期:2021-02-26 出版日期:2022-01-15 发布日期:2022-01-20
通讯作者: ^*谢雁鸣,首席研究员,博导,中药上市后评价研究及老年病。E-mail：ktzu2018@163.com
作者简介:孙春全,男,博士,老年病。
基金资助:
国家重点研发计划（2018YFC1707400）

Clinical characteristics and combined medication of Shengmai injection in the treatment of 9215 elderly patients with cardiovascular diseases

SUN Chunquan¹, XIE Yanming^1,*, HOU Hengyue²

¹Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China;
²School of Statistics, Renmin University of China, Beijing 100872, China

Received:2021-02-26 Online:2022-01-15 Published:2022-01-20

摘要/Abstract

摘要： 目的为深入研究真实世界中生脉注射液（SMI）治疗老年心血管疾病的临床特征,以医院信息管理系统（hospital information system, HIS）为基础,进行了生脉注射液的真实世界研究。方法利用R软件对HIS数据库中2001年1月1日至2016年12月31日29家三甲医院的9 215例老年心血管疾病患者数据进行数据挖掘,分析患者的临床特征、生脉注射液的用药特点。结果男性患者（5 109例）多于女性（4 035例）,性别不详71例;平均年龄（78.15±6.90）岁,平均住院天数（25.39±19.88）d,高血压、呼吸道感染、心律失常为最常见的合并疾病,主要用药途径为静脉滴注（7 504例）,静脉滴注的单次使用剂量平均（55.79±18.06）mL,平均用药疗程（6.02±7.37）d。最为常用的用药组合包括痰热清注射液+氨溴索等。结论通过对HIS数据库老年心血管疾病的挖掘分析,可初步掌握患者的基本特征、生脉注射液的用药特征,为指导临床医生合理联合应用生脉注射液提供参考。

关键词: 真实世界, 生脉注射液, 老年心血管疾病, 医院信息管理系统, 临床特征

Abstract: Objective To conduct a real-world study of Shengmai injection based on the hospital information system (HIS) in order to find out more about the clinical characteristics of elderly patients with cardiovascular diseases who use Shengmai injection (SMI). Methods The clinical data on 9 215 elderly patients with cardiovascular diseases treated in 29 tertiary hospitals between January 1, 2001 and December 31, 2016 was retrieved from the HIS database by R software to analyze the clinical characteristics of patients and ways in which Shengmai injection was used. Results There were 5 109 male patients and 4 035 female ones involved. The average age of these patients was (78.15±6.90) years, and their length of hospital stay averaged (25.39±19.88) days. Hypertension, respiratory tract infection and arrhythmia were the most common comorbidities. The main route of administration of SMI was intravenous drip (7 504 cases) and the average single dose was (55.79±18.06) ml. The average duration of treatment was (6.02±7.37) days. The most commonly used drug combinations included Tanreqing injection+ambroxol. Conclusion Analysis of the data on elderly patients with cardiovascular diseases has revealed some of the characteristics of these patients and ways of medication of SMI, which can help clinicians to use SMI rationally.

Key words: real world, Shengmai injection, cardiovascular diseases in the elderly, hospital information system, clinical characteristics

中图分类号:

R994.11

孙春全, 谢雁鸣, 侯恒悦. 真实世界生脉注射液治疗9215例老年心血管疾病的临床特征及联合用药研究[J]. 中国药物警戒, 2022, 19(1): 36-40.

SUN Chunquan, XIE Yanming, HOU Hengyue. Clinical characteristics and combined medication of Shengmai injection in the treatment of 9215 elderly patients with cardiovascular diseases[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 36-40.

参考文献

[1] WU JR, YANG SY, ZHANG XM, et al.Systematic review of Shengmai injection in the treatment of coronary heart disease and angina pectoris based on meta-analysis[J]. Journal of Chinese Experimental Prescriptions(中国实验方剂学杂志), 2015, 21(22): 222-225.
[2] WANG LM, GAO CJ, XIE LC, et al.Clinical study of Shengmai injection combined with lyophilized recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction with heart failure[J]. Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular and Cerebrovascular Diseases(中西医结合心脑血管病杂志), 2019,17(22): 3553-3556.
[3] ZHUANG Y, XIE BT, WENG SX, et al.Discussion on the design method of his“real world”integrated data warehouse for post marketing reevaluation of traditional Chinese medicine[J]. Journal of Traditional Chinese Medicine(中国中药杂志), 2011, 36(20): 2880.
[4] Drug intelligence data. Drug ATC code query system[EB/OL]. [2021-03-11] https://db.yaozh.com/atc/.2014-4-17/2019-9-15.
[5] National Pharmacopoeia Commission.Pharmacopoeia (Part I) of the People's Republic of China[中华人民共和国药典(一部)][M]. Beijing: China Pharmaceutical Science and Technology Press, 2020.
[6] The People's Government of the People's Republic of China. The Department of Human Resources and Social Security of the State Medicare Administration is concerned with the publication of the national basic medical insurance, workers'insurance and fertility insurance drug catalog (2020) notice[EB / OL]http://www.gov.cn/zhengce/zhengceku/2020-12/28/content_5574062.htm,202020-12-28/2021-03-11.
[7] CHEN Z, WU JJ.Research on medical data mining based on association rules[J]. Statistics and Decision(统计与决策), 2020, 36(6): 174-177.
[8] YANG ZJ, TANG M.Risk factors analysis of cardiovascular disease in elderly patients with coronary heart disease[J]. Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular and Cerebrovascular Diseases(中西医结合心脑血管病杂志), 2018,16(20): 3010-3013.
[9] HU MY, ZHAO Y, XU X, et al.Correlation between different blood glucose levels and cardiovascular risk factors in elderly patients with type 2 diabetes[J]. Journal of Chinese Diabetes(中国糖尿病杂志), 2015, 23(12): 1092-1095.
[10] LUO YZ, ZHAO YH, ZHANG HG.Analysis of the related factors of pulmonary infection in patients with coronary heart disease[J]. Journal of Chinese Hospital Infectiology(中华医院感染学杂志), 2014, 24(13): 3245-3247.
[11] LIU LN, ZHU XL, MA HF, et al.Meta analysis on risk factors of secondary pulmonary infection in Chinese elderly patients with heart failure[J]. Journal of Chinese Gerontology(中国老年学杂志), 2019, 39(23): 5652-5657.
[12] LIAO XJ, YIN T, LI CM, et al.Discussion on the relationship between over instructions of traditional Chinese medicine injection and adverse reactions[J]. Journal of Pharmacoepidemiol(药物流行病学杂志), 2018, 2(2): 104-108.
[13] LI WJ, LI XY, FAN XL.Overview of the consequences and causes of overdose of traditional Chinese medicine injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2011, 8(10): 611-613.
[14] KERNIS SJ, HARJAI KJ, STONE GW, et al.Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty[J]. J Am Coll Cardiol, 2004, 43(10): 1773-1779.
[15] XIAO Y, DONG PS, YANG XM.Expression of serum inflammatory factors in patients with acute coronary syndrome with pulmonary infection[J]. Journal of Chinese Hospital Infectiology(中华医院感染学杂志), 2015, 25(18): 4138-4140.
[16] Guidelines for rational use of drug in coronary heart disease (2nd edition)[J]. Journal of Chinese Medical Frontier (electronic edition)中国医学前沿杂志(电子版), 2018, 10(6): 1-130.
[17] FARIS RF, FLATHER M, PURCELL H, et al. Diuretics for heart failure[J]. Cochrane Database Syst Rev, 2012(2): CD003838.
[18] LIU Y, GAO ZY, FU CG, et al.Prevention and treatment of coronary heart disease by promoting blood circulation and removing blood stasis drugs: evidence based and prospect[J]. Journal of Chinese Evidence Based Medicine(中国循证医学杂志), 2018, 18(11): 1145-1150.
[19] FAN CP, DU HG, TIAN Y.Clinical application of Tanreqing injection in respiratory diseases[J]. Chinese Traditional Medicine Emergencies(中国中医急症), 2014, 23(10): 1878-1881.

真实世界生脉注射液治疗9215例老年心血管疾病的临床特征及联合用药研究

Clinical characteristics and combined medication of Shengmai injection in the treatment of 9215 elderly patients with cardiovascular diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	史卜文, 李利寻, 谢雁鸣, 王志飞, 王淇. 真实世界喜炎平注射液治疗3846例细菌性肠道感染患者临床用药特征分析[J]. 中国药物警戒, 2023, 20(9): 1017-1021.
[2]	赵燕, 刘文博, 赵一飞, 李栋, 郑立佳, 宋雅娜, 赵玉娟, 董放. 患者登记研究应用于医疗器械监管科学的实践研究与思考[J]. 中国药物警戒, 2023, 20(4): 423-427.
[3]	杜莹, 谢雁鸣, 王连心, 耿洪娇, 李向杰. 真实世界连花清瘟胶囊（颗粒）适应证人群临床特征及联合用药分析[J]. 中国药物警戒, 2023, 20(3): 296-300.
[4]	杜莹, 赵晓晓, 谢雁鸣, 余小康. 基于真实世界使用榄香烯乳状注射液影响肝功能的倾向性评分分析[J]. 中国药物警戒, 2023, 20(2): 191-195.
[5]	王嘉熙, 郭代红, 张博, 李伯妍, 郭海丽. 116097例氟比洛芬酯用药人群的急性肾损伤自动监测研究及危险因素分析[J]. 中国药物警戒, 2023, 20(2): 201-205.
[6]	吴昀效, 于玥琳, 王胜锋, 孙凤, 孟若谷, 詹思延. 真实世界数据在疫苗上市后安全性主动监测中适用性评价分析[J]. 中国药物警戒, 2023, 20(10): 1081-1089.
[7]	苏鑫鑫, 赵晓晓, 谢雁鸣. 榄香烯乳注射液治疗肝癌患者的真实世界联合用药分析[J]. 中国药物警戒, 2022, 19(9): 929-934.
[8]	黄艳丽, 谢雁鸣, 王连心, 孙粼希, 刘峘, 庄鋆妮. 真实世界老年患者使用刺五加注射液的临床分析[J]. 中国药物警戒, 2022, 19(9): 935-939.
[9]	赵晓晓, 谢雁鸣, 王连心. 真实世界榄香烯乳状注射液治疗肺癌临床应用特征研究[J]. 中国药物警戒, 2022, 19(9): 940-946.
[10]	谭畅, 赵晓晓, 支英杰, 王连心, 谢雁鸣. 榄香烯乳状注射液治疗脑瘤人群临床特征及联合用药的复杂网络分析[J]. 中国药物警戒, 2022, 19(9): 947-953.
[11]	杜莹, 王志飞, 谢雁鸣, 王连心, 李利寻, 刘志帅. 喜炎平注射液治疗手足口病人群的联合用药方案复杂网络分析[J]. 中国药物警戒, 2022, 19(8): 839-844.
[12]	董晗硕, 孙莉, 赵晓晓, 王连心, 余小康, 谢雁鸣. 真实世界榄香烯乳状注射液用于老年人群的临床特征及联合用药分析[J]. 中国药物警戒, 2022, 19(8): 845-850.
[13]	张宏伟, 黎元元, 谢雁鸣, 马晓昌, 王连心, 魏瑞丽, 孙粼希, 徐鸿燕, 庄严. 真实世界中丹参川芎嗪注射液联合用药特征研究[J]. 中国药物警戒, 2022, 19(8): 851-856.
[14]	张蕾, 黎元元, 谢雁鸣, 王连心, 杨晓晨. 注射用灯盏花素治疗心绞痛真实世界研究[J]. 中国药物警戒, 2022, 19(8): 857-861.
[15]	姚羽, 黎元元, 魏戌, 谢雁鸣, 王志飞, 高明慧. 真实世界中鹿瓜多肽注射液疑似过敏反应影响因素研究[J]. 中国药物警戒, 2022, 19(7): 740-743.